RFK Jr. Says He Won't Put Anti-Vaxxers on Key Vaccine Panel
Health Secretary Robert F. Kennedy Jr. pledged to bring in 'highly credentialed physicians' and 'not anti-vaxxers' to fill newly vacant slots on an influential committee that advises the US government on vaccine policy.
Kennedy made the remarks roughly 24 hours after he abruptly dismissed all 17 members of the Advisory Committee on Immunization Practices in an unprecedented move he said was needed to restore public confidence in vaccine science. The new members will be in place before the panel's next scheduled meeting that starts June 25, Kennedy said Tuesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Factbox-Breakdown of U.S. tariffs on China since Trump's first term
BEIJING (Reuters) -Billions of dollars of Chinese goods have been impacted by additional U.S. tariffs since 2018, initially under the first Donald Trump presidency and later under the Biden administration. Returning to the White House this year, Trump has imposed even more duties on China. The U.S. tariffs range from those imposed under Section 301 of its trade act due to what Washington claims are unfair Chinese trade practices, to duties under Section 232 levied for national security reasons. This year, Trump has imposed another 20% levies on all Chinese goods, saying Beijing has not done enough to stop the flow of fentanyl into the United States. So-called reciprocal tariffs, under which the U.S. will match duties imposed by other countries, have also been levied in a bid to rebalance trade flows. Below are the U.S. tariffs on China effective as of June 12, 2025: Tariff Rate Products Effective date Reciprocal 10% All Paused for 90 days until Aug 10, 2025 Fentanyl 20% All Mar 4, 2025 Section Up to List 1: Pharmaceuticals, July 6, 2018 301 25% iron and steel, aluminium, vehicles and aircraft, medical or surgical instruments and apparatus and more. List 2: Vehicles, Aug 23, 2018 railway or tramway locomotives, aircraft and their parts, medical or surgical instruments and apparatus and more. List 3: Prepared May 10, 2019 foodstuffs, beverages, mineral products, fertilizers, wood products, textiles, precious and base metals, vehicles, aircraft, vessels, machinery and mechanical appliances and more. List 4A: Prepared Feb 14, 2020 foodstuffs, beverages, mineral products, fertilizers, footwear, wood products, ceramic products, glass, textiles, precious and base metals, machinery and mechanical appliances, vehicles, aircraft, vessels, art, antiques and more. In September 2019, the U.S. imposed 15% tariffs on more than $120 billion of Chinese goods under Section 301, which it then halved to 7.5% less than six months later. The 25% U.S. tariffs on $250 billion of Chinese goods under the earlier List 1-3 remain unchanged. In September 2024, the U.S. Trade Representative under the Biden administration announced additional tariffs of 25-100% on 14 product groups following a four-year review of the Section 301 tariff actions. The levies were imposed on strategic Chinese sectors or sectors where the United States has made significant domestic investments. Additional tariffs on goods under Section 301: Effective date EVs 100% Sep 27, 2024 Solar cells, syringes and 50% needles Non-lithium-ion battery parts, 25% lithium-ion electrical vehicle batteries, other critical minerals, ship-to-shore cranes, steel and aluminium products, facemasks Semiconductors 50% Jan 1, 2025 Lithium-ion non-electrical 25% Jan 1, 2026 vehicle batteries, medical gloves, natural graphite, permanent magnets In addition to the above duties, the first Trump administration in 2018 imposed a range of tariffs under Section 232 aimed at restricting goods deemed a threat to national security, including all aluminium and steel imports, shutting most Chinese suppliers out of the U.S. market. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships. FP008, Fapon Biopharma's lead asset, is a first-in-class immunocytokine currently in Phase 1 clinical trials, designed to address significant unmet needs in solid tumor patient refractory to anti-PD-1 therapy. The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities. Fapon Biopharma will feature its proprietary and innovative technology platforms, engineered to overcome complex drug development challenges: Bi/Tri-TCE Platform: Human-monkey cross-reactive TCR/CD3 nanobody, enabling the design of potent multi-specific antibodies for targeted cancer immunotherapy. FILTEN™ (IL-10M Fusion Protein Platform): Overcoming IL-10 limitations for broad applications in cancer and autoimmune diseases PROTiNb™ (Proteolysis Targeting Intra-Nanobody): A pioneering platform targeting previously "undruggable" intracellular targets, demonstrating a strong competitive edge. FIND™ Mammalian Cell Display Platform: Accelerating antibody discovery by combining mammalian cell expression with high-throughput screening. "We are excited to connect with the global biopharma community at BIO 2025," said Vincent Huo, President of Fapon Biopharma. "We look forward to demonstrating the exciting progress of our internal pipeline and how our technology platforms can empower external partners to bring transformative therapy to patients faster." Engagement Opportunities:Exhibition Booth: #1851Company Presentation: Time: 11:30 a.m., Tuesday, June 17, 2025Location: Room 153A, Boston Convention & Exhibition Center To schedule a meeting in advance or during the conference, please contact our BD representatives, Max Wang ( and Liyan Gao ( or visit us at Booth #1851. Meetings can also be requested via the BIO partnering system. About Fapon Biopharma ( Fapon Biopharma specializes in discovering and developing biologics for treating cancers, autoimmune diseases and other diseases where there are unmet medical needs. Leveraging cutting-edge technologies, we have built advanced drug discovery platforms, including an antibody discovery platform based on the globally leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. With a differentiated pipeline of leading drug candidates, we have established capabilities that cover the entire drug development process from drug discovery, preclinical research, Chemistry, Manufacturing and Controls (CMC) to early clinical development. Committed to innovation, we strive to deliver safer, more efficacious, affordable, and accessible biologics for everyone. View original content to download multimedia: SOURCE Fapon Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
29 minutes ago
- Associated Press
Pakistan crackdown sends Afghan families to unknown future
Pakistan wants to expel three million Afghans by the end of this year, saying they are in the country illegally, but many have lived there for decades. Returning refugees have been forced to head to a camp across the border, in Torkham, where thousands arrive every week and face a new future in a country they don't know. Pakistan denies targeting Afghans and says everyone leaving is treated humanely and with dignity.
